search
Back to results

NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction

Primary Purpose

Opiate Addiction

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Methadone
Diamorphine hydrochloride
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opiate Addiction focused on measuring Opiate addiction, medical heroin, methadoneRCT

Eligibility Criteria

25 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Opioid Dependence as confirmed by DSM-IV diagnostic criteria 25 years of age or older 5 years or more of opioid use Regular opioid injection use in the past month and in at least 8 months in the past 12 months (self reported; regular use - defined as injecting opioids for at least 4 days or more in a week); 50% or more of the injections during the prior year must have involved heroin). Minimum of one-year residence in site/city location No enrollment in any other opioid substitution (e.g. methadone) program within the prior 6 months - enrollment is defined as having received at least 45 milligrams of prescribed methadone per day on any 30 consecutive days or more in the prior 6 months At least two previous episodes of opiate addiction treatment (methadone maintenance, detoxification, residential care, etc) during which, on at least one occasion, the patient received at least 60 mg of methadone daily for at least 30 days in a 40 day period Willingness and ability to adhere to study protocol and follow-up schedule as determined through the three-week pre-randomization period (see Section C.4) Documentation of fulfillment of the above study criteria (prison records, treatment records, cohort study enrollment, urine sampling) Provide written and informed consent. Exclusion Criteria: Diagnosis of severe medical or psychiatric conditions that are contra-indicated for heroin treatment Pregnancy upon study entry On parole or with current justice system involvement that is likely to result in an extended period of incarceration (more than 4 months) during the study period (e.g. scheduled trial for an indictable offense, jail, etc) Hydromorphone is a class C teratogen and should not be given to pregnant women. All female subjects upon study entry will be urged to engage only in protected sexual intercourse and will provide consent to undergo monthly pregnancy tests during the course of the study. Serum bilirubin >2.5 x normal Stage II or greater hepatic encephalopathy Chronic respiratory disease resulting in resting respiratory rate >20/minute Bipolar Mood Disorder, Schizophrenia or other psychotic disorder with active psychotic symptoms within the past 6 months Major Depression refractory to medical management or requiring electroconvulsive therapy within the past 12 months.

Sites / Locations

  • University of British Columbia Faculty of Medicine
  • University of Montreal

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

1

2

Arm Description

Oral methadone

Injected diacetylmorphine

Outcomes

Primary Outcome Measures

Recruitment and retention in the study at 12 months
Illicit drug use and criminal behavior at 12 months.

Secondary Outcome Measures

social integration, functioning, quality of life at 12 and 24 months; and cost-effectiveness at 12 months

Full Information

First Posted
September 9, 2005
Last Updated
September 25, 2014
Sponsor
University of British Columbia
Collaborators
Canadian Institutes of Health Research (CIHR)
search

1. Study Identification

Unique Protocol Identification Number
NCT00175357
Brief Title
NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction
Official Title
North American Opiate Medication Initiative (NAOMI): Multi-Centre, Randomized Controlled Trial of Heroin-Assisted Therapy for Treatment-Refractory Injection Opiate Users
Study Type
Interventional

2. Study Status

Record Verification Date
September 2014
Overall Recruitment Status
Completed
Study Start Date
March 2005 (undefined)
Primary Completion Date
April 2007 (Actual)
Study Completion Date
April 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of British Columbia
Collaborators
Canadian Institutes of Health Research (CIHR)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to determine whether the closely supervised provision of injectable, pharmaceutical-grade heroin (in combination with oral methadone) is more effective than methadone therapy alone in recruiting, retaining, and benefiting long-term heroin users who have not been helped by current standard treatment options.
Detailed Description
This is a two-centre (Vancouver, Montreal) RCT involving a total of 235 volunteers. Eligible participants will be randomized to injectable heroin combined with oral methadone as desired (45%) versus oral methadone alone (45%). A subset of 10% will be randomized to injectable hydromorphone (Dilaudid™). Hydromorphone and heroin will be given in a double-blind fashion; the purpose is to permit validation of reported illicit use of heroin through urine testing in the hydromorphone group. Research visits will be conducted quarterly and will occur independently of treatment clinic visits. Incentives will be used to maintain research follow-up whether or not the subject is retained in treatment. The analysis will be under intent-to-treat. The primary outcomes of interest are 1) recruitment and retention in the study and 2) illicit drug use and criminal behavior (as determined by the Europ-ASI) at 12 months. Secondary outcomes are measures of social function (e.g., social integration and functioning, quality of life) and cost-benefit/effectiveness of the interventions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Opiate Addiction
Keywords
Opiate addiction, medical heroin, methadoneRCT

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
192 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Oral methadone
Arm Title
2
Arm Type
Experimental
Arm Description
Injected diacetylmorphine
Intervention Type
Drug
Intervention Name(s)
Methadone
Intervention Description
The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
Intervention Type
Drug
Intervention Name(s)
Diamorphine hydrochloride
Intervention Description
The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
Primary Outcome Measure Information:
Title
Recruitment and retention in the study at 12 months
Time Frame
12 months
Title
Illicit drug use and criminal behavior at 12 months.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
social integration, functioning, quality of life at 12 and 24 months; and cost-effectiveness at 12 months
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Opioid Dependence as confirmed by DSM-IV diagnostic criteria 25 years of age or older 5 years or more of opioid use Regular opioid injection use in the past month and in at least 8 months in the past 12 months (self reported; regular use - defined as injecting opioids for at least 4 days or more in a week); 50% or more of the injections during the prior year must have involved heroin). Minimum of one-year residence in site/city location No enrollment in any other opioid substitution (e.g. methadone) program within the prior 6 months - enrollment is defined as having received at least 45 milligrams of prescribed methadone per day on any 30 consecutive days or more in the prior 6 months At least two previous episodes of opiate addiction treatment (methadone maintenance, detoxification, residential care, etc) during which, on at least one occasion, the patient received at least 60 mg of methadone daily for at least 30 days in a 40 day period Willingness and ability to adhere to study protocol and follow-up schedule as determined through the three-week pre-randomization period (see Section C.4) Documentation of fulfillment of the above study criteria (prison records, treatment records, cohort study enrollment, urine sampling) Provide written and informed consent. Exclusion Criteria: Diagnosis of severe medical or psychiatric conditions that are contra-indicated for heroin treatment Pregnancy upon study entry On parole or with current justice system involvement that is likely to result in an extended period of incarceration (more than 4 months) during the study period (e.g. scheduled trial for an indictable offense, jail, etc) Hydromorphone is a class C teratogen and should not be given to pregnant women. All female subjects upon study entry will be urged to engage only in protected sexual intercourse and will provide consent to undergo monthly pregnancy tests during the course of the study. Serum bilirubin >2.5 x normal Stage II or greater hepatic encephalopathy Chronic respiratory disease resulting in resting respiratory rate >20/minute Bipolar Mood Disorder, Schizophrenia or other psychotic disorder with active psychotic symptoms within the past 6 months Major Depression refractory to medical management or requiring electroconvulsive therapy within the past 12 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin T Schechter, MD, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of British Columbia Faculty of Medicine
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
University of Montreal
City
Montreal
State/Province
Quebec
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
25262567
Citation
Oviedo-Joekes E, Marchand K, Lock K, Chettiar J, Marsh DC, Brissette S, Anis AH, Schechter MT. A chance to stop and breathe: participants' experiences in the North American Opiate Medication Initiative clinical trial. Addict Sci Clin Pract. 2014 Sep 29;9(1):21. doi: 10.1186/1940-0640-9-21.
Results Reference
derived
PubMed Identifier
24908387
Citation
Oviedo-Joekes E, Guh D, Marchand K, Marsh DC, Lock K, Brissette S, Anis AH, Schechter MT. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment. Subst Abuse Treat Prev Policy. 2014 Jun 8;9:23. doi: 10.1186/1747-597X-9-23.
Results Reference
derived
PubMed Identifier
22276954
Citation
Marchand K, Oviedo-Joekes E, Guh D, Marsh DC, Brissette S, Schechter MT. Sex work involvement among women with long-term opioid injection drug dependence who enter opioid agonist treatment. Harm Reduct J. 2012 Jan 25;9:8. doi: 10.1186/1477-7517-9-8.
Results Reference
derived
PubMed Identifier
21791093
Citation
Marchand KI, Oviedo-Joekes E, Guh D, Brissette S, Marsh DC, Schechter MT. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency. BMC Health Serv Res. 2011 Jul 26;11:174. doi: 10.1186/1472-6963-11-174.
Results Reference
derived
PubMed Identifier
19692689
Citation
Oviedo-Joekes E, Brissette S, Marsh DC, Lauzon P, Guh D, Anis A, Schechter MT. Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009 Aug 20;361(8):777-86. doi: 10.1056/NEJMoa0810635.
Results Reference
derived
PubMed Identifier
19159475
Citation
Gartry CC, Oviedo-Joekes E, Laliberte N, Schechter MT. NAOMI: The trials and tribulations of implementing a heroin assisted treatment study in North America. Harm Reduct J. 2009 Jan 21;6:2. doi: 10.1186/1477-7517-6-2.
Results Reference
derived
Links:
URL
http://www.naomistudy.ca
Description
Related Info

Learn more about this trial

NAOMI: A Study to Compare Medically-prescribed Heroin With Oral Methadone in Chronic Opiate Addiction

We'll reach out to this number within 24 hrs